NASDAQ · Biotechnology

CDT (CDT) Stock

$3.14 +9.60% NASDAQ: CDT Healthcare

Valuation

MetricValue
Price$3.14
Market Cap$1.53M
P/E Ratio0.00
P/B Ratio0.01
P/S Ratio0.01
EPS (TTM)$0.00
52-Week High$610.00
52-Week Low$0.32
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE18.83%
ROA6.72%
ROCE24.98%
Gross Margin11.60%
Operating Margin11.64%
Net Margin2.38%
Debt/Equity1.05
Current Ratio1.94

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$2.7B
Operating Profit$-3.0M$-3.0M$-5.0M$-15.0M$316.0M
Net Profit$-4.0M$-5.0M$-1.0M$-18.0M$238.0M
EPS$-252.50$-16.87$-900.00$-5132.50$1477.50
Op Margin————11.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$0$7.0M$4.0M$3.5B
Total Liabilities$0$10.0M$8.0M$11.0M$2.3B
Cash$0$0$4.0M$1.0M$390.0M
Borrowings$0$2.0M$1.0M$7.0M$1.3B

Latest News

CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane GlobeNewswire · Jul 20, 2026 CDT Equity Implements 1-for-10 Reverse Stock Split MT Newswires · Jul 16, 2026 CDT Equity Inc. Announces Reverse Stock Split GlobeNewswire · Jul 16, 2026 CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development GlobeNewswire · Jun 26, 2026 BC-Most Active Stocks Associated Press · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-2.0M$-8.0M$-10.0M$-16.0M
Investing Cash Flow$0$0$1.0M$0$-3.0M
Financing Cash Flow$0$0$9.0M$0$0
Net Cash Flow$0$0$4.0M$-4.0M$1.0M
Free Cash Flow$-2.0M$-2.0M$-8.0M$-10.0M$-18.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA2.45
FCF Yield-81.71%
Quick Ratio1.40
Interest Coverage6.87
Return 1Y-99.92%
Return 3Y-100.00%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About CDT

CDT is led by CEO Andrew Regan, employs 6 people, headquartered in US, publicly traded since 2022.

CDT stock trades at $3.14 with a market capitalization of $1.53M. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.01, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.32 and $610.00, and currently trades 99.5% below its 52-week high.

On profitability, CDT generates a return on equity (ROE) of 18.83%, above the typical market average, return on capital employed of 24.98%, an operating margin of 11.64%, a net profit margin of 2.38%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides